Filing Details
- Accession Number:
- 0001179110-13-006105
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-04-01 19:36:43
- Reporting Period:
- 2013-03-28
- Filing Date:
- 2013-04-01
- Accepted Time:
- 2013-04-01 19:36:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1197018 | Anthony N Coles | C/O Onyx Pharmaceuticals, Inc. 249 E. Grand Ave. South San Francisco CA 94080 | Chairman & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-03-28 | 10,938 | $35.18 | 119,392 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-03-28 | 10,938 | $90.00 | 108,454 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2013-03-28 | 26,800 | $0.00 | 135,254 | No | 4 | A | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | A | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2013-03-28 | 10,938 | $0.00 | 10,938 | $35.18 |
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2013-03-28 | 75,300 | $0.00 | 75,300 | $88.86 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
54,687 | 2021-03-31 | No | 4 | M | Direct | |
75,300 | 2023-03-27 | No | 4 | A | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 Plan.
- Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock units vest annually over four years.
- 12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting of 48 months.
- Includes shares purchased through the issuer's ESPP.